Taiko Pharmaceutical Co.,Ltd. (TYO:4574)
Japan
· Delayed Price · Currency is JPY 290.00
-9.00 (-3.01%)
At close: Mar 9, 2026
Taiko Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 6,397 | 6,292 | 6,120 | 5,040 | 11,299 | Upgrade
|
| Revenue Growth (YoY) | 1.67% | 2.81% | 21.43% | -55.39% | -49.68% | Upgrade
|
| Cost of Revenue | 2,916 | 2,626 | 3,543 | 3,961 | 8,552 | Upgrade
|
| Gross Profit | 3,481 | 3,666 | 2,577 | 1,079 | 2,747 | Upgrade
|
| Selling, General & Admin | 3,022 | 3,036 | 3,583 | 4,157 | 7,694 | Upgrade
|
| Operating Expenses | 3,022 | 3,036 | 3,583 | 4,157 | 7,694 | Upgrade
|
| Operating Income | 459 | 630 | -1,006 | -3,078 | -4,947 | Upgrade
|
| Interest Expense | -5 | -8 | -8 | -10 | -6 | Upgrade
|
| Interest & Investment Income | 16 | 30 | 25 | 5 | 3 | Upgrade
|
| Currency Exchange Gain (Loss) | 138 | 39 | 31 | 59 | 50 | Upgrade
|
| Other Non Operating Income (Expenses) | 3 | -2 | -291 | -330 | -1,231 | Upgrade
|
| EBT Excluding Unusual Items | 611 | 689 | -1,249 | -3,354 | -6,131 | Upgrade
|
| Gain (Loss) on Sale of Investments | 347 | 6 | 193 | -82 | 60 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 76 | - | - | Upgrade
|
| Asset Writedown | -26 | -240 | -2,506 | -98 | -2,456 | Upgrade
|
| Legal Settlements | - | - | - | -499 | -359 | Upgrade
|
| Other Unusual Items | 14 | 111 | -78 | -837 | -2 | Upgrade
|
| Pretax Income | 958 | 566 | -3,564 | -4,870 | -8,888 | Upgrade
|
| Income Tax Expense | 35 | -332 | 47 | 25 | 706 | Upgrade
|
| Net Income | 923 | 898 | -3,611 | -4,895 | -9,594 | Upgrade
|
| Net Income to Common | 923 | 898 | -3,611 | -4,895 | -9,594 | Upgrade
|
| Net Income Growth | 2.78% | - | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 50 | 50 | 47 | 44 | 44 | Upgrade
|
| Shares Outstanding (Diluted) | 50 | 50 | 47 | 44 | 44 | Upgrade
|
| Shares Change (YoY) | 0.11% | 5.96% | 8.62% | 0.21% | 0.35% | Upgrade
|
| EPS (Basic) | 18.37 | 17.89 | -76.25 | -112.27 | -220.51 | Upgrade
|
| EPS (Diluted) | 18.37 | 17.89 | -76.25 | -112.27 | -220.51 | Upgrade
|
| EPS Growth | 2.67% | - | - | - | - | Upgrade
|
| Free Cash Flow | 523 | 205 | -404 | -2,058 | -3,071 | Upgrade
|
| Free Cash Flow Per Share | 10.41 | 4.08 | -8.53 | -47.20 | -70.58 | Upgrade
|
| Dividend Per Share | 3.300 | - | - | - | - | Upgrade
|
| Gross Margin | 54.42% | 58.26% | 42.11% | 21.41% | 24.31% | Upgrade
|
| Operating Margin | 7.17% | 10.01% | -16.44% | -61.07% | -43.78% | Upgrade
|
| Profit Margin | 14.43% | 14.27% | -59.00% | -97.12% | -84.91% | Upgrade
|
| Free Cash Flow Margin | 8.18% | 3.26% | -6.60% | -40.83% | -27.18% | Upgrade
|
| EBITDA | 724 | 886 | -302 | -2,341 | -4,006 | Upgrade
|
| EBITDA Margin | 11.32% | 14.08% | -4.93% | -46.45% | -35.45% | Upgrade
|
| D&A For EBITDA | 265 | 256 | 704 | 737 | 941 | Upgrade
|
| EBIT | 459 | 630 | -1,006 | -3,078 | -4,947 | Upgrade
|
| EBIT Margin | 7.17% | 10.01% | -16.44% | -61.07% | -43.78% | Upgrade
|
| Effective Tax Rate | 3.65% | - | - | - | - | Upgrade
|
| Advertising Expenses | - | 767 | 979 | 806 | 3,005 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.